In Oct 2007, the FDA declared the labeling for all PDE5 inhibitors, such as tadalafil, requires a more popular warning of the opportunity hazard of unexpected hearing reduction as the result of submit-marketing and advertising reports of short-term deafness related to use of PDE5 inhibitors.[19]Obvladovanje zelo zahtevnih, kompleksnih delovnih proc